nach oben

Journal of Neurology

Erschienen in:

02.04.2021 | Original Communication

Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients

verfasst von: Yuki Fukami, Masahiro Iijima, Haruki Koike, Shinichiro Yamada, Atsushi Hashizume, Masahisa Katsuno

Erschienen in: Journal of Neurology | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To clarify whether serum neurofilament light chains (NfLs) serve as a biomarker of axonal damage in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), especially in patients with anti-neurofascin 155 (NF155) antibodies.

Methods

The Simoa system was used to examine serum NfL levels from 58 patients with CIDP, including 13 anti-NF155 antibody-positive patients, and from 14 age- and sex-matched healthy individuals. Serum NfL levels were evaluated before and after treatment in eight patients with anti-NF155 antibodies. Clinical features, electrophysiological findings, and cerebrospinal fluid (CSF) protein levels, were evaluated. The pathological features of sural nerves from 40 patients were also examined.

Results

Serum NfL levels were significantly higher in patients with CIDP than in healthy individuals (median 29.63 vs. 7.71 pg/mL, p < 0.001) and were correlated with both modified Rankin Scale scores (r = 0.584, p < 0.001) and CSF protein levels (r = 0.432, p = 0.001). The NfL levels of anti-NF155 antibody-positive patients were higher than those of antibody-negative patients (p = 0.005). Serum NfL levels were negatively correlated with compound muscle action potential amplitudes of the tibial nerves (r = − 0.404, p = 0.004) and positively correlated with the degree of active axonal degeneration in the pathological findings (r = 0.485, p = 0.001). In the antibody-positive group, NfL levels and antibody titers decreased after treatment in all examined patients.

Conclusion

Serum NfL correlated with pathological indices of axonal degeneration, and may serve as a biomarker that reflects active axonal damage of CIDP.

Nur mit Berechtigung zugänglich

Dyck PJ, Lais AC, Ohta M et al (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50(11):621–637PubMed

Van den Bergh PY, Hadden RD, Bouche P et al (2010) European Federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force of the European Federation of Neurological societies and the peripheral nerve society – first revision. J Peripher Nerv Syst 15(3):185–195CrossRef

Dalakas MC (2011) Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7(9):507–517CrossRef

Latov N (2014) Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol 10(8):435–446CrossRef

Bunschoten C, Jacobs BC, Van den Bergh PYK et al (2019) Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 18(8):784–794CrossRef

Koike H, Katsuno M (2020) Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy. Neurol Ther. https://doi.org/10.1007/s40120-020-00190-8CrossRefPubMedPubMedCentral

Ng JK, Malotka J, Kawakami N et al (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79(23):2241–2248CrossRef

Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2013) Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73(3):370–380CrossRef

Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886CrossRef

10.

Doppler K, Appeltshauser L, Wilhelmi K et al (2015) Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 86(7):720–728CrossRef

11.

Miura Y, Devaux JJ, Fukami Y et al (2015) Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138(6):1484–1491CrossRef

12.

Ogata H, Yamasaki R, Hiwatashi A et al (2015) Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2(10):960–971CrossRef

13.

Devaux JJ, Miura Y, Fukami Y et al (2016) Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86(9):800–807CrossRef

14.

Koike H, Kadoya M, Kaida KI et al (2017) Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88(6):465–473CrossRef

15.

Vallat JM, Yuki N, Sekiguchi K et al (2017) Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. Neuromuscul Disord 27(3):290–293CrossRef

16.

Koike H, Nishi R, Ikeda S et al (2018) Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology 91(23):1051–1060CrossRef

17.

Iijima M, Yamamoto M, Hirayama M et al (2005) Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64(8):1471–1475CrossRef

18.

Rajabally YA (2015) Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 51(5):657–661CrossRef

19.

Notturno F, Capasso M, DeLauretis A et al (2009) Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies. Muscle Nerve 40(1):50–54CrossRef

20.

Wong AH, Fukami Y, Sudo M et al (2016) Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 87(3):275–279CrossRef

21.

Allen JA, Merkies ISJ, Lewis RA (2020) Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol 77(9):1159–1166CrossRef

22.

Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247–2257CrossRef

23.

Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20PubMed

24.

Preische O, Schultz SA, Apel A et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 25(2):277–283CrossRef

25.

Mattsson N, Andreasson U, Zetterberg H et al (2017) Alzheimer’s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in with alzheimer disease. JAMA Neurol 74(5):557–566CrossRef

26.

Lycke JN, Karlsson JE, Andersen O et al (1998) Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64(3):402–404CrossRef

27.

Malmeström C, Haghighi S, Rosengren L et al (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61(12):1720–1725CrossRef

28.

Gunnarsson M, Malmeström C, Axelsson M et al (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69(1):83–89CrossRef

29.

Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92(10):e1007–e1015CrossRef

30.

Sandelius Å, Zetterberg H, Blennow K et al (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90(6):e518–e524CrossRef

31.

Mariotto S, Farinazzo A, Magliozzi R et al (2018) Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23(3):174–177CrossRef

32.

van Lieverloo GGA, Wieske L, Verhamme C et al (2019) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24(2):187–194CrossRef

33.

Ikeda S, Koike H, Nishi R et al (2019) Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90(9):988–996CrossRef

34.

Dyck PJ, Dyck PJB, Engelstad J (2005) Pathologic alterations of nerves. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, pp 733–829CrossRef

35.

Gafson AR, Barthélemy NR, Bomont P et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143(7):1975–1998CrossRef

36.

Lombardi V, Querin G, Ziff OJ et al (2019) Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92(11):e1205–e1211PubMedPubMedCentral

37.

Kapoor M, Foiani M, Heslegrave A et al (2019) Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst 24(4):314–319CrossRef

38.

Shimizu F, Sawai S, Sano Y et al (2014) Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS ONE 9(8):e104205CrossRef

39.

Mariotto S, Carta S, Bozzetti S et al (2020) Sural nerve biopsy: current role and comparison with serum neurofilament light chain levels. J Neurol 267(10):2881–2887CrossRef

40.

Fujita A, Ogata H, Yamasaki R et al (2018) Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 384:107–112CrossRef

41.

Shimizu S, Iijima M, Fukami Y et al (2020) Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized Placebo-Controlled Clinical Trial. JMIR Res Protoc 9(4):e17117CrossRef

Titel: Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients
verfasst von: Yuki Fukami
Masahiro Iijima
Haruki Koike
Shinichiro Yamada
Atsushi Hashizume
Masahisa Katsuno
Publikationsdatum: 02.04.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 10/2021
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10537-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Balance and coordination training for patients with genetic degenerative ataxia: a systematic review

Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing–remitting multiple sclerosis

Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review

MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study

Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis